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I n the treatment of oral squamous cell carcinoma (OSCC),  patients with clinically diagnosed cervical 
lymph node (LN) metastases are subjected to radical 
neck dissection or modified radical neck dissection.  
The existence of extranodular spread (ENS) influences 
the method selection [1].
In previous studies,  the sensitivity and specificity of 
computed tomography (CT) for predicting ENS were 
reported to be about 81% and 73% [2],  and those of 
MRI about 74% and 72% [3].  Another study reported 
that 60-min 18F-fluorodeoxyglucose positron emission 
tomography (18F-FDG PET/CT) was useful for predict-
ing ENS,  with sensitivity and specificity of 85% and 
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The aim of this study was to evaluate the ability of pretreatment 90-min 18F-fluorodeoxyglucose positron emis-
sion tomography/computed tomography (18F-FDG PET/CT) to predict the extranodular spread of lymph node 
metastases in oral squamous cell carcinoma.  We retrospectively reviewed the cases of 56 patients who under-
went pretreatment 18F-FDG PET/CT and surgery with neck dissection.  Maximum standardized uptake value,  
metabolic tumor volume,  and total lesion glycolysis were measured for the 56 primary sites and maximum 
standardized uptake value was measured for 115 lymph node levels.  Extranodular spread was present at 9 
lymph node levels in 7 patients.  Significant differences were found in metabolic tumor volume and total lesion 
glycolysis of the primary site,  and in lymph node maximum standardized uptake value,  between patients with 
and without extranodular spread (p< 0.05).  Combining primary site total lesion glycolysis and lymph node 
maximum standardized uptake volume at their respective optimal cutoffs,  the sensitivity,  specificity,  and accu-
racy for predicting extranodular spread were 89%,  92%,  and 92%,  respectively.  Pretreatment 18F-FDG PET/CT 
is useful for predicting extranodular spread in patients with oral squamous cell carcinoma.  The combined use of 
primary site total lesion glycolysis and lymph node maximum standardized uptake value showed greater pre-
dictive value than either predictor singly.
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88%,  respectively,  using a maximum standardized 
uptake (SUVmax) value of 2.25 as the cutoff for LN [4].  
However,  the detection of cervical LNs with an 
SUVmax of 2.25 is clinically difficult,  because adjacent 
tissues or substances to which the 18F-FDG are also 
taken up,  such as plaque in the carotid artery,  have 
SUVmax values within the same range [5].
In contrast,  measuring the 18F-FDG uptake of the 
primary site (PS) is relatively easy.  Moreover,  previous 
reports have demonstrated the utility of measuring the 
PS 18F-FDG uptake for predicting LN metastases in 
patients with primary lung carcinoma and OSCC in 
whom the 18F-FDG uptake to metastatic LNs was nega-
tive [6 , 7].  Furthermore,  several recent papers revealed 
that metabolic tumor volume (MTV) and total lesion 
glycolysis (TLG) were more useful prognostic markers 
compared to SUVmax [7-10].
We hypothesized that the evaluation of the 18F-FDG 
accumulation at the PS could be another potential pre-
dictor of ENS in patients with OSCC.  To the best of our 
knowledge,  the correlation between ENS and the 18F-
FDG uptake at the PS,  and the possibility of diagnosing 
ENS by evaluating the 18F-FDG accumulation at the PS 
have not been clarified.  Moreover,  no report has 
assessed the utility of 90-min 18F-FDG PET/CT for the 
prediction of LN metastases in OSCC.
In this retrospective study,  we compared four 
parameters collected by pretreatment with 90-min 18F-
FDG PET/CT—SUVmax for PS (SUV-PS),  MTV for PS 
(MTV-PS),  TLG for PS (TLG-PS),  and SUVmax of LN 
itself (SUV-LN)—for their ability to predict ENS in 
OSCC.
Materials and Methods
Patient population. We retrospectively reviewed 
the medical records of 56 patients with newly diagnosed 
OSCC who underwent pretreatment 18F-FDG PET/CT 
for initial staging between August 2010 and November 
2016 (28 males,  28 females; age [mean ± SD],  70.43 ±  
13.40; range,  23-92 years).  All patients underwent 
resection of the primary tumor and neck dissection 
with curative intent,  and histological diagnosis of the 
primary tumor and lymph nodes was performed.  
Seventeen patients underwent comprehensive neck dis-
section,  and 39 patients underwent selective neck dis-
section (Level 1,  n=11; Level 2,  n=1; Level 1-2,  n=2;  
Level 1-3,  n = 14; Level 1-4,  n = 11).  Exclusion criteria 
were a previous history of malignancy within 5 years,  
induction chemotherapy,  and a serum glucose level of 
more than 150 mg/dl prior to the radiotracer injection.
Data were obtained from medical records,  including 
clinicopathological variables and treatment.  Tumors 
were staged according to the TNM Classification of 
Malignant Tumors,  8th edition [11].  The study was 
approved by the institutional review board of our hospi-
tal and the requirement of informed consent was waived 
(1811-012).
18F-FDG PET/CT procedures and analysis of PET/
CT images. All 18F-FDG PET/CT examinations were 
performed using an integrated PET/CT scanner 
(Biograph 16; Siemens Medical Solution USA,  
Knoxville,  TN,  USA) at a diagnostic imaging center 
adjacent to our institution.  After fasting for at least 5 h,  
the patients received an intravenous injection of 
3.7 MBq/kg 18F-FDG.  At our institution,  PET image 
acquisition is routinely started 90 min after injection of 
18F-FDG,  with the patient in a relaxed supine position.  
First,  a total-body low-dose CT scan for the calculation 
of attenuation correction was performed,  using a stan-
dardized protocol involving 120 kV,  auto mA mode,  
rotation time of 0.5 sec,  pitch of 0.8,  section thickness 
of 3 mm,  and scan field from the head to the mid-thigh 
level.  Immediately thereafter,  PET imaging consisting 
of 6-8 bed positions with 2.4 min per position over the 
same region was performed.  The PET images were 
reconstructed with an ordered-subset expectation max-
imization iterative reconstruction algorithm.
Integrated,  co-registered PET/CT images were 
obtained using a workstation that enables image fusion 
and analysis (syngo.  via; Siemens Medical Solution 
USA).  For semi-quantitative analyses of 18F-FDG 
uptake,  the images were evaluated by 2 nuclear medi-
cine physicians,  by consensus.  A volume of interest was 
drawn semi-automatically over the PS and all measur-
able dissected cervical LN levels on an axial slice.  If 18F-
FDG uptake was perceptible in a cervical LN,  the 
SUVmax in the cervical LN was measured to minimize 
partial-volume effects [12 , 13].  If multiple nodes in the 
same LN level were measurable,  the highest SUVmax 
value among them was adopted as the representative 
SUVmax of the LN level.  For calculating MTV and 
TLG,  the threshold values were set at an SUV of 2.5,  
based on the results of previous studies [8 , 9 , 14].  The 
semi-quantitative values of SUV-PS,  MTV-PS,  TLG-PS 
and SUV-LN were calculated automatically.
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Statistical analyses. All analyses were performed 
using IBM SPSS Statistics (version 22; IBM Corp.,  
Armonk,  NY,  USA).  The Mann-Whitney U test was 
used to analyze differences in SUV-PS,  MTV-PS,  
TLG-PS,  or SUV-LN between the groups with and 
without ENS.  Receiver operating characteristic (ROC) 
curve analysis of such semi-quantitative parameters was 
performed to differentiate the tumors with ENS from 
those without ENS,  and to differentiate the LN levels 
with ENS from those without ENS.  P values < 0.05 were 
considered statistically significant.
Results
Characteristics of patients and oral squamous cell 
carcinoma. Table 1 shows the patients’ characteris-
tics.  Seven out of 56 patients had 9 LNs with patholog-
ically proven ENS in 115 dissected LN levels.  The pri-
mary tumor size ranged from 12 to 85 mm,  with most 
lesions being < 50 mm in the long axis diameter.  
Figures 1 and 2 show representative 18F-FDG PET/CT 
images of OSCC with and without ENS.
Standardized uptake value, metabolic tumor vol-
ume, and total lesion glycolysis. Table 2 shows the 
SUV-PS,  MTV-PS,  TLG-PS,  and SUV-LN values in the 
study groups.  The SUV-PS (mean ± SD) values in 
patients with and without ENS were 16.84 ± 4.95 and 
12.54 ± 5.98,  the MTV-PS values in patients with and 
without ENS were 27.05±12.25 ml and 14.09±13.36 ml,  
and the TLG-PS values in patients with and without 
ENS were 153.03 ± 68.13 g and 80.85 ± 111.30 g,  respec-
tively.  The SUV-LN values in patients with and without 
ENS were 8.18 ± 4.43 and 2.69 ± 2.37.  Significant inter-
group differences were found in MTV-PS,  TLG-PS,  
and SUV-LN (all p < 0.05) but not in SUV-PS (p = 0.12).
The areas under the ROC curve (AUCs) for SUV-PS,  
MTV-PS,  TLG-PS,  and SUV-LN were 0.684 (p = 0.12,  
95% CI 0.534-0.834),  0.812 (p = 0.008,  95% CI 0.697-
0.937),  0.816 (p = 0.007,  95% CI 0.676-0.956),  and 
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Lymph node size (mm)
　　Mean±SD/Range 18.1±9.8/10-44 9.6±3.6/4-23
ENS,  extranodular spread; SD,  standard deviation; UICC 8th,  TNM 
classification of malignant tumors,  8th edition,  by UICC.
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Fig. 1　 An 89-year-old woman with left lower gingival squamous 
cell carcinoma and level I cervical lymph node metastasis with 
extranodular spread.  Axial computed tomography (CT) (A) shows 
soft tissue density in the primary site (arrowhead) and an enlarged 
level I lymph node (arrow).  Positron emission tomography (PET) 
(B),  positron emission tomography/computed tomography (PET/
CT) (C),  and maximum intensity projection (MIP) (D) images show 
high 18F-FDG uptake of the primary site (SUVmax,  MTV,  and TLG 
were 28.54,  25.19 ml,  and 178.53 g,  respectively) and lymph node 
(SUVmax was 8.85),  which is easy to distinguish from adjacent 
tissues.
0.932 (p < 0.001,  95% CI 0.882-0.982) with the optimal 
cut-off values of 13.46,  19.56 ml,  106.26 g,  and 3.37,  
respectively (Fig. 3A , 3B).  The sensitivity,  specificity,  
and accuracy for predicting ENS using these cut-off 
values were 86%,  78%,  and 80% for MTV-PS,  and 
86%,  78%,  and 80% for TLG-PS,  respectively.  The 
sensitivity,  specificity,  and accuracy of SUV-LN levels 
for predicting ENS were 100%,  84%,  and 86% using the 
optimal cut-off value.
A predictor combining TLG in the primary tumor 
and SUVmax in lymph nodes. TLG-PS showed a 
higher AUC than SUV-PS or MTV-PS,  and SUV-LN 
demonstrated the highest AUC among all parameters.  
Combining the two criteria—namely,  considering a 
TLG-PS greater than 106.26 g and an SUV-LN greater 
than 3.37—resulted in sensitivity,  specificity,  and accu-
racy of 89%,  92%,  and 92%,  respectively,  for the pre-
diction of ENS.
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Table 2　 Comparison of the measured parameters between the 
ENS and the non-ENS groups
ENS group non-ENS group p value＊
Primary site
　　SUVmax 16.84±4.95 12.54±5.98 0.12
(13.16-28.54) (3.38-29.15)
　　MTV (ml) 27.05±12.25 14.09±13.36 0.006
(11.75-54.57) (0.99-83.12)
　　TLG (g) 153.03±68.13 80.85±111.30 0.005
(52.34-289.91) (2.89-759.97)
Lymph node
　　SUVmax 8.18±4.43 2.69±2.37 ＜0.001
(3.37-19.5) (1.08-17.02)
ENS,  extranodular spread; SUVmax,  maximum standardized 
uptake value; MTV,  metabolic tumor volume; TLG,  total lesion 
glycolysis.  The data are represented as mean±standard deviation,  
data in parentheses are the range.
＊P value: comparison of semiquantitative values between the ENS 
and non-ENS groups (Mann-Whitney U-test).
Ａ Ｂ
Ｃ Ｄ
Fig. 2　 A 90-year-old woman with right tongue squamous cell 
carcinoma and level II cervical lymph node metastasis without extra-
nodular spread.  Axial computed tomography (CT) (A) shows slightly 
higher density of the primary site (arrowhead) than the other side,  
and a conspicuous level II lymph node (arrow).  Positron emission 
tomography (PET) (B),  positron emission tomography/computed 
tomography (PET/CT) (C),  and maximum intensity projection 
(MIP) (D) images show intense 18F-FDG uptake to the primary site 
(SUVmax,  MTV,  and TLG of the primary site were 16.73,  
12.97 ml,  and 77.54 g,  respectively) and intense 18F-FDG uptake of 
the lymph node (SUVmax,  2.94).  The SUVmax of the primary site 
was relatively high,  but the MTV and the TLG of the primary site 


















Fig. 3A　 Receiver operating characteristics (ROC) curves for 
patients with ENS according to maximum standardized uptake value 
(SUVmax),  metabolic tumor volume (MTV),  and total lesion glycol-
ysis (TLG) of the primary site show the discrimination achieved by 
each parameter in the extranodular spread (ENS) group and the 
non-ENS groups.
Discussion
Several previous studies have investigated the utility 
of SUVmax measured by 18F-FDG PET/CT for predict-
ing LN metastases in patients with OSCC [15-17].  
MTV is a measure of the volume of the tumor display-
ing 18F-FDG uptake,  and thus quantifies the overall 
tumor burden,  and is theoretically a better predictor of 
outcome than the SUVmax [18].  TLG represents the 
metabolic activity throughout the entire tumor above a 
minimum threshold designed to exclude the back-
ground activity [19].  Therefore,  volume-based param-
eters such as MTV and TLG may reflect the metabolic 
burden of the active tumor more accurately than 
SUVmax and thus could be better surrogate imaging 
markers of tumor biology [7 , 20 , 21].
The first finding in the present study was that 
MTV-PS,  TLG-PS,  and SUV-LN were useful parame-
ters to predict LNs with ENS in our study population.  
In a previous study [4],  ENS could be predicted using a 
SUV-LN cut-off value of 2.25,  with 85% sensitivity and 
88% specificity.  However,  in clinical practice,  detecting 
cervical LNs with an SUVmax of 2.25 is difficult,  
because adjacent tissues or substances to which the 18F-
FDG are also taken up have SUVmax values within the 
same range [5].  In contrast,  MTV-PS and TLG-PS can 
be easily measured in clinical practice.  Moreover,  the 
combined use of TLG-PS and SUV-LN exhibited a 
higher performance for predicting ENS than the use of 
either parameter alone,  with 89% sensitivity,  92% spec-
ificity,  and 92% accuracy.  Therefore,  these results sug-
gest that measuring TLG-PS in addition to SUV-LN on 
pretreatment 18F-FDG PET/CT could be both feasible 
and useful to predict LNs with ENS in patients with 
OSCC.
The second finding of our study is that the optimal 
cut-off value of SUV-LN was 3.37,  with 100% sensitiv-
ity,  84% specificity,  and 86% accuracy in predicting 
ENS,  and an AUC value of 0.932 ± 0.05.  In a previous 
study [4] of OSCC patients with 71 dissected LN levels,  
the SUV-LN in the tumors with ENS was greater than 
that in those without ENS,  and the difference was sig-
nificant.  The ROC curve analysis of SUV-LN in the 
same study showed an AUC of 0.864 ± 0.045 and an 
optimal SUVmax cut-off value of 2.25,  with 85% sensi-
tivity and 88% specificity.  In our study,  we achieved 
excellent diagnostic capacity by setting the SUV-LN 
cut-off value at 3.37.  In clinical practice,  it is relatively 
easy to detect LNs with an SUVmax greater than 3.37,  
even when surrounded by adjacent normal tissue with 
physiological uptake.  The difference in diagnostic per-
formance of SUV-LN between our study and the previ-
ous study [4] could be due to the difference in the PET 
acquisition time point.  PET image acquisitions were 
started at 90 min after injection of 18F-FDG in the pres-
ent study and at 60 min after injection in the previous 
study [4].  Another previous research on 2-h dual-time-
point 18F-FDG PET demonstrated that head and neck 
malignant tumors had a mean SUV increase of 12% 
between the 1-h (early) and the 2-h (late) phases,  and 
that the 18F-FDG uptake to inflammation and normal 
tissue had meanwhile decreased [22].  Another recent 
report revealed that the 18F-FDG uptake to most normal 
cervical tissue decreases as time proceeds within 3 h 
after 18F-FDG injection [23].  These results suggest that 
90-min PET acquisition with SUV-LN measurement is 
superior to 60-min PET acquisition for the prediction of 
ENS in OSCC,  and that the contrast between metastatic 
LNs with ENS and surrounding normal tissue might be 
better on 90-min than 60-min PET images.
This study has several limitations.  First,  it is inher-
ently limited by its retrospective nature.  Second,  the 
study population was relatively small,  especially in 
terms of patients having tumors with ENS.  Finally,  
PET image acquisition was performed only at 90 min 
and not at 60 min.  A multi-institutional trial using a 
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Fig. 3B　 Receiver operating characteristics (ROC) curves for 
lymph nodes with ENS according to the maximum standardized 
uptake value (SUVmax) of the lymph node show the performance of 
the discrimination between the extranodular spread (ENS) group 
and the non-ENS groups.
larger patient population with 90-min dual-time-point 
18F-FDG PET/CT may provide a clearer picture and 
more confident assessment of the ability of 90-min 18F-
FDG PET/CT to predict ENS in patients with OSCC.
In conclusion,  the findings of the present study 
demonstrate that the assessment of 18F-FDG MTV-PS 
and TLG-PS could be a useful and highly accurate tool 
for predicting ENS in patients with OSCC.  The 90-min 
18F-FDG PET/CT is potentially more useful than the 
60-min 18F-FDG PET/CT for predicting ENS by evalu-
ating the 18F-FDG accumulation to LNs.  Specifically,  
on 90-min 18F-FDG PET/CT,  a TLG-PS cut-off value of 
106.26 g,  combined with a SUV-LN cut-off value of 
3.37,  demonstrated excellent diagnostic performance in 
identifying lymph nodes with ENS in OSCC patients.
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